4.7 Article

PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes

期刊

ISCIENCE
卷 23, 期 1, 页码 -

出版社

CELL PRESS
DOI: 10.1016/j.isci.2019.100750

关键词

-

资金

  1. U.S. Army Medical Research Acquisition Activity, Prostate Cancer Research Program [PC11190, PC120512, PC150697]
  2. NCI [RO1CA212403]
  3. Purdue University Center for Cancer Research Small Grants
  4. Indiana University Simon Cancer Center [P30CA082709]
  5. Purdue University Center for Cancer Research
  6. Walther Cancer Foundation
  7. NCI CCSG [CA23168]
  8. Indiana University Precision Health Initiative
  9. Indiana Clinical and Translational Sciences Institute (CTSI) Pre-Doctoral Fellowship [TL1 TR001107, TL1 TR002531, UL1 TR001108, UL1 TR002529]
  10. National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award

向作者/读者索取更多资源

DNA double-strand break (DSB) repair is critical for cell survival and genome integrity. Upon recognition of DSBs, repair proteins are transiently upregulated to facilitate repair through homologous recombination (HR) or non-homologous end joining (NHEJ). We present evidence that PRMT5 cooperates with pICln to function as a master epigenetic activator of DNA damage response (DDR) genes involved in HR, NHEJ, and G(2) arrest (including RAD51, BRCA1, and BRCA2) to upregulate gene expression upon DNA damage. Contrary to the predominant role of PRMT5 as an epigenetic repressor, our results demonstrate that PRMT5 and pICln can activate gene expression, potentially independent of PRMT5's obligate cofactor MEP50. Targeting PRMT5 or plCln hinders repair of DSBs in multiple cancer cell lines, and both PRMT5 and pICln expression positively correlates with DDR genes across 32 clinical cancer datasets. Thus, targeting PRMT5 or pICln may be explored in combination with radiation or chemotherapy for cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据